Literature DB >> 28389859

A method to slow down the ionization-dependent release of risperidone loaded in a thermoresponsive poly(N-acryloyl glycinamide) hydrogel.

Mahfoud Boustta1, Michel Vert2.   

Abstract

Poly(N-acryloyl glycinamide) polymers are soluble in hot aqueous media that gel rapidly on cooling. This gelatin-like behavior was previously compared with drug delivery requirements. Slow releases were demonstrated in vitro using different model molecules and macromolecules and in vivo using methylene blue. Risperidone is a weak basic drug sparingly soluble in water frequently used to treat patients suffering of schizophrenia. A standard risperidone-poly(N-acryloyl glycinamide) hydrogel formulation was selected from which the drug was allowed to release comparatively in buffered and non-buffered isotonic media at 37 °C under pseudo sink conditions. Linear release was observed in pH = 7.4 phosphate buffer whereas in buffer-free 0.15 M NaCl, the release was initially faster than in the buffer but became rapidly slower as the pH increased from 6.8 to 8.2. These features were related to the ionization-dependent solubility of risperidone. In order to minimize the ionization and thus the solubility of the drug inside the hydrogel despite outside buffering at 7.4, Mg(OH2), a sparingly soluble mineral base, was added to the standard formulation. This addition resulted in a c.a. threefold increase of the zero-order release duration. The method should be applicable to other sparingly soluble weakly basic drugs.

Entities:  

Keywords:  Gel-sol transition; Hydrogel; Magnesium hydroxide; PNAGA; Poly(N-acryloyl glycinamide); Risperidone; Sustained drug delivery; Thermoresponsive hydrogel; UCST; Weak base

Mesh:

Substances:

Year:  2017        PMID: 28389859     DOI: 10.1007/s13346-017-0376-5

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  7 in total

1.  A study of drug release from homogeneous PLGA microstructures.

Authors:  Ghanashyam Acharya; Crystal S Shin; Kumar Vedantham; Matthew McDermott; Thomas Rish; Keith Hansen; Yourong Fu; Kinam Park
Journal:  J Control Release       Date:  2010-04-08       Impact factor: 9.776

2.  In vitro and in vivo demonstration of risperidone implants in mice.

Authors:  C Rabin; Y Liang; R S Ehrlichman; A Budhian; K L Metzger; C Majewski-Tiedeken; K I Winey; S J Siegel
Journal:  Schizophr Res       Date:  2007-08-31       Impact factor: 4.939

3.  Versatile UCST-based thermoresponsive hydrogels for loco-regional sustained drug delivery.

Authors:  Mahfoud Boustta; Pierre-Emmanuel Colombo; Sébastien Lenglet; Sylvain Poujol; Michel Vert
Journal:  J Control Release       Date:  2013-11-08       Impact factor: 9.776

4.  Effect of bases with different solubility on the release behavior of risperidone loaded PLGA microspheres.

Authors:  Zhenhua Hu; Yajun Liu; Weien Yuan; Fei Wu; Jing Su; Tuo Jin
Journal:  Colloids Surf B Biointerfaces       Date:  2011-04-08       Impact factor: 5.268

Review 5.  Overview on Therapeutic Applications of Microparticulate Drug Delivery Systems.

Authors:  Swarna Bale; Amit Khurana; A Shiva Shankar Reddy; Mandip Singh; Chandraiah Godugu
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2016       Impact factor: 4.889

6.  In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia.

Authors:  Laura C Amann; Michael J Gandal; Robert Lin; Yuling Liang; Steven J Siegel
Journal:  Pharm Res       Date:  2010-04-27       Impact factor: 4.200

7.  Serum concentrations and side effects in psychiatric patients during risperidone therapy.

Authors:  O V Olesen; R W Licht; E Thomsen; T Bruun; J E Viftrup; K Linnet
Journal:  Ther Drug Monit       Date:  1998-08       Impact factor: 3.681

  7 in total
  1 in total

1.  Modulation of Transaminase Activity by Encapsulation in Temperature-Sensitive Poly(N-acryloyl glycinamide) Hydrogels.

Authors:  Katrin Kappauf; Nikola Majstorovic; Seema Agarwal; Dörte Rother; Christiane Claaßen
Journal:  Chembiochem       Date:  2021-10-13       Impact factor: 3.461

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.